Adonix: what is in it and what the evidence actually shows

A man standing calmly after training on a sunlit stone terrace beside an olive tree

Adonix is a named combination of tesamorelin, ipamorelin, AOD-9604, and MOTS-C. Its components sit in growth hormone and metabolic signalling research. No controlled human trial of this specific four-part combination was identified, so anything said about it is extrapolated from work on the individual substances.

Composition

  • tesamorelin
  • ipamorelin
  • aod-9604
  • mots-c

Overview

Adonix groups four substances that appear in overlapping bodies of research: two that act on growth hormone release, one fragment derived from the growth hormone molecule, and one mitochondrial-derived peptide. The shared research theme is signalling around growth hormone and energy handling rather than any single demonstrated result. This page exists so that a reader can see the exact composition, understand what each component has and has not been studied for, and take specific questions into a physician evaluation.

Why these are grouped

The rationale offered for grouping these four is that they touch different points in the same signalling conversation. Tesamorelin and ipamorelin act upstream on growth hormone release through different receptors. AOD-9604 is a fragment of the growth hormone molecule that was studied for metabolic effects rather than growth hormone release. MOTS-C comes from a separate line of mitochondrial research. That is a mechanistic story, not a finding. Grouping substances that each have separate literature does not create evidence that the group works together.

What each ingredient contributes

tesamorelin

A growth hormone releasing hormone analogue with an FDA-approved product for one specific indication. In this grouping it is the component with the most developed human data, though that data does not describe this combination.

ipamorelin

A growth hormone secretagogue studied for its selectivity in preclinical work. It is included as a second, different route to the same axis rather than for any established added benefit.

aod-9604

A fragment of the growth hormone molecule investigated in human obesity trials that did not establish it as an approved therapy. It is present for its metabolic research history, not for growth hormone release.

mots-c

A mitochondrial-derived peptide studied mainly in animal and cell models of metabolic signalling. Human data are minimal, and its inclusion is mechanistic reasoning rather than a demonstrated contribution.

Combination evidence

  • No published randomized controlled trial, cohort study, or registered clinical trial of the exact Adonix combination was identified.
  • Because there is no combination study, there is no published safety profile, no published adverse event rate, and no published outcome data for these four substances given together.
  • Any claim that this combination performs better than one component alone would be unsupported by current literature.

Tesamorelin has substantial human trial data for one FDA-approved indication. AOD-9604 has human obesity trial data that did not lead to approval. Ipamorelin and MOTS-C are supported mainly by preclinical work. Evidence about a single substance describes that substance under the conditions it was studied. It does not transfer to a four-part mixture, and combining individually studied substances does not produce additive benefit unless a study shows it.

Preclinical rationale

  • Growth hormone releasing hormone analogues and growth hormone secretagogues act through separate receptor pathways, which is the stated reason two of them appear together.
  • AOD-9604 was designed around the fat-metabolism region of the growth hormone molecule and was studied without the growth-promoting portion.
  • MOTS-C appears in animal work on metabolic and mitochondrial signalling, largely in models rather than in people.

What is not established

  • Whether the four components interact favourably, neutrally, or unfavourably in humans.
  • Whether any effect attributed to the combination exceeds what a single component would produce.
  • Long-term safety of sustained multi-component signalling on the growth hormone axis.
  • Effects in people with diabetes, active or prior cancer, or pituitary disease, groups typically excluded from the underlying trials.

Questions to discuss with a physician

  • Given my history, is there any reason to consider the growth hormone axis at all?
  • Which single component, if any, has evidence that applies to my situation?
  • What would you monitor, and what result would make you stop?
  • What are the realistic alternatives, including doing nothing?
  • How would we tell which component caused a side effect?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.